Infections

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Neoplasms

Blood and Lymph Conditions

COVID-19

Hematologic Neoplasms

Neoplasms, Second Primary

Hematologic Diseases

All Drugs and Chemicals

Antibodies

Vaccines

Immunomodulating Agents

Immunoglobulins

Patients with malignant disease undergoing chemotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.

Patients with malignant disease undergoing chemotherapy + immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.

Patients with malignant disease undergoing immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.

Patients with malignant disease treated with targeted therapies within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.

Patients with malignant disease undergoing radiotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.

Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.

Data collection

Luis TEIXEIRA, MD, PhD

Gérard ZALCMAN, MD, PhD

In the context of malignant disease, it is likely that vaccine efficacy and immunogenicity depends on the type of pathology, stage of the disease, immunosuppression induced by the treatments, in addition to more classic factors such as age, general condition and possibly the type of vaccine used.

There are very little data on the efficacy and immunogenicity of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with malignant disease in the active phase of treatment.

This multicenter observational study aims to assess the efficacy and the immunogenicity of anti-Sars-CoV-2 vaccines in the cohort of patients treated for malignant pathology (solid or hematological tumors) at Saint Louis Hospital and in thoracic oncology patients at Bichat Hospital.

During the visit carried out as part of the follow-up, participation in this study will be proposed to any patient who is treated for a malignant disease (solid or hematological tumors) within the university hospitals of AP-HP.Nord.

The patients participating in this prospective cohort will benefit from all standard care his/her condition requires.

Clinical and biological data will be collected as part of the usual follow-up. Clinical data: pathology, stage, treatment line, type of current treatment and date of the last treatment administered, previous treatments, radiotherapy, concept of radiation lung disease, history of pneumonectomy, comorbidities, performance status, history of coronavirus disease 2019 (COVID-19).

Laboratory data: pre-vaccination polynuclear neutrophil count, lymphocyte counts, plasma protein electrophoresis or Ig weight dosage (routine care in hematology), lactate dehydrogenase (LDH), C-reactive protein (CRP), albuminemia in the previous month.

Vaccination data: type of vaccine, date of the 1st injection, date of the 2nd injection, pre-vaccination antibody levels

* Seroconversion with anti-S IgG after anti-Sars-CoV-2 vaccination
* Anti-S and / or anti-N Sars-CoV-2 IgG seroprevalence before vaccination
* Adverse effects related to vaccines
* Levels of the anti-S IgG antibodies in AU / ml

During visits between D21 and D28 (before the 2nd injection), at month 3, month 6 and month 12, the following data will be collected:

* Antibody levels
* Adverse effects related to vaccines
* Levels of the anti-S IgG antibodies in AU / ml
* Associated side effects
* Occurrence of COVID-19.

COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies

Multicenter, Observational Study of Anti-Sars-Cov2 Vaccine Efficacy in Patients With Malignant Pathologies Treated in the University Hospitals of AP-HP. Nord

IgG anti-Sarc-CoV-2 S-protein titer at 12 months

Rate of patients presenting the anti Sarc-CoV-2 S-protein antibodies before vaccination in the study population.

Rate of patients presenting the anti Sarc-CoV-2 N-protein antibodies before vaccination in the study population.

IgG anti-Sarc-CoV-2 S-protein titer after the first injection of vaccine

IgG anti-Sarc-CoV-2 S-protein titer at 3 months

IgG anti-Sarc-CoV-2 S-protein titer at 6 months

Occurence of the adverse events related to the SARS-CoV-2 vaccine

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies	NCT04776005	Solid Tumor Hematologic Mal... Thoracic Cancer Cancer, Treatme... Vaccine Respons...	Data collection	18 Years -	Assistance Publique - Hôpitaux de Paris
COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies	NCT04776005	Solid Tumor Hematologic Mal... Thoracic Cancer Cancer, Treatme... Vaccine Respons...	Data collection	18 Years -	Assistance Publique - Hôpitaux de Paris

Spots Global Cancer Trial Database for malignant pathology